TY - JOUR
T1 - D-Limonene
T2 - A bioactive food component from citrus and evidence for a potential role in breast cancer prevention and treatment
AU - Miller, Jessica A.
AU - Thompson, Patricia A.
AU - Hakim, Iman A.
AU - Chow, H. H.Sherry
AU - Thomson, Cynthia A.
PY - 2011/3
Y1 - 2011/3
N2 - Although limited, observations from cell culture, animal, and epidemiological studies support the presence of anti-cancer properties in citrus peel and the primary bioactive food constituent, d-limonene. Early evidence from animal models suggests that when ingested, d-limonene exhibits a wide spectrum of biologic activity including chemotherapeutic and chemopreventive effects. In some of these early models, an analog of d-limonene, perillyl alcohol, demonstrated a more potent effect than d-limonene itself. Yet, when perillyl alcohol advanced to clinical trials, several trials were ended early due to dose-limiting toxicities. Alternatively, oral d-limonene administration in humans is well tolerated even at high doses supporting its investigation as a potential bioactive for cancer prevention. Though the exact mechanisms of action of d-limonene are unclear, immune modulation and anti-proliferative effects are commonly reported. Here, we review the pre-clinical evidence for d-limonene's anti-cancer mechanisms, bioavailability, and safety, as well as the evidence for anti-cancer effects in humans, focusing on studies relevant to its use in the prevention and treatment of breast cancer.
AB - Although limited, observations from cell culture, animal, and epidemiological studies support the presence of anti-cancer properties in citrus peel and the primary bioactive food constituent, d-limonene. Early evidence from animal models suggests that when ingested, d-limonene exhibits a wide spectrum of biologic activity including chemotherapeutic and chemopreventive effects. In some of these early models, an analog of d-limonene, perillyl alcohol, demonstrated a more potent effect than d-limonene itself. Yet, when perillyl alcohol advanced to clinical trials, several trials were ended early due to dose-limiting toxicities. Alternatively, oral d-limonene administration in humans is well tolerated even at high doses supporting its investigation as a potential bioactive for cancer prevention. Though the exact mechanisms of action of d-limonene are unclear, immune modulation and anti-proliferative effects are commonly reported. Here, we review the pre-clinical evidence for d-limonene's anti-cancer mechanisms, bioavailability, and safety, as well as the evidence for anti-cancer effects in humans, focusing on studies relevant to its use in the prevention and treatment of breast cancer.
KW - Bioactive food component
KW - Breast cancer
KW - Perillyl alcohol
KW - d-Limonene
UR - http://www.scopus.com/inward/record.url?scp=79954575341&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79954575341&partnerID=8YFLogxK
U2 - 10.1007/s12156-010-0066-8
DO - 10.1007/s12156-010-0066-8
M3 - Review article
AN - SCOPUS:79954575341
SN - 1970-5557
VL - 5
SP - 31
EP - 42
JO - Oncology Reviews
JF - Oncology Reviews
IS - 1
ER -